Maynard Um
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX)
-
-
-
-
-
-
-
Regenxbio Inc. (RGNX) PT Lowered to $18 at Leerink Partners
-
-
-
-
-
-
-
Regenxbio Inc. (RGNX) PT Lowered to $12 at Goldman Sachs
-
-
-
-
-
-
-
Stifel on Regenxbio Inc. (RGNX): PT $45, 'should NOT impact RGX-202 and RGX-314'
-
-
-
-
-
-
-
Regenxbio (RGNX) files mixed shelf
-
-
-
-
-
-
-
Raymond James on Regenxbio Inc. (RGNX): 'we think FDA guidance is strongly supportive of HS D2S6 as a biomarker'
-
-
-
-
-
-
-
Regenxbio (RGNX) Misses Q2 EPS by 44c
-
406,474 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

